Literature DB >> 24679681

Clinical predictors of response to anakinra in patients with heart failure.

Justin M Canada1, Benjamin W Van Tassell2, Sanah Christopher1, Claudia Oddi1, Nayef A Abouzaki1, Michael L Gambill1, George Mueller1, Ryan Melchior1, Keyur B Shah1, Charles A Dinarello3, Antonio Abbate1, Ross Arena4.   

Abstract

Entities:  

Keywords:  Aerobic capacity; Diastole; Heart failure; Inflammation

Mesh：

Substances：

Year:  2014        PMID： 24679681      PMCID： PMC4518460          DOI： 10.1016/j.ijcard.2014.03.023

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  17 in total

Review 1.  Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association.

Authors:  Gary J Balady; Ross Arena; Kathy Sietsema; Jonathan Myers; Lola Coke; Gerald F Fletcher; Daniel Forman; Barry Franklin; Marco Guazzi; Martha Gulati; Steven J Keteyian; Carl J Lavie; Richard Macko; Donna Mancini; Richard V Milani
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

Review 2.  The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: a mini review.

Authors:  Marco Guazzi; Ross Arena
Journal:  Curr Vasc Pharmacol       Date:  2009-10       Impact factor: 2.719

3.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).

Authors:  Paul M Ridker; Tom Thuren; Andrew Zalewski; Peter Libby
Journal:  Am Heart J       Date:  2011-09-14       Impact factor: 4.749

Review 4.  A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure.

Authors:  Lawrence P Cahalin; Paul Chase; Ross Arena; Jonathan Myers; Daniel Bensimhon; Mary Ann Peberdy; Euan Ashley; Erin West; Daniel E Forman; Sherry Pinkstaff; Carl J Lavie; Marco Guazzi
Journal:  Heart Fail Rev       Date:  2013-01       Impact factor: 4.214

Review 5.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

Authors:  Barry A Borlaug; Walter J Paulus
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

Review 6.  Natriuretic peptides.

Authors:  Lori B Daniels; Alan S Maisel
Journal:  J Am Coll Cardiol       Date:  2007-12-18       Impact factor: 24.094

7.  Inflammation in chronic heart failure.

Authors:  Roy C Parish; Jeffery D Evans
Journal:  Ann Pharmacother       Date:  2008-05-27       Impact factor: 3.154

Review 8.  Targeting interleukin-1 in heart disease.

Authors:  Benjamin W Van Tassell; Stefano Toldo; Eleonora Mezzaroma; Antonio Abbate
Journal:  Circulation       Date:  2013-10-22       Impact factor: 29.690

9.  Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.

Authors:  John J V McMurray; John Kjekshus; Lars Gullestad; Peter Dunselman; Ake Hjalmarson; Hans Wedel; Magnus Lindberg; Finn Waagstein; Peer Grande; Jaromir Hradec; Gabriel Kamenský; Jerzy Korewicki; Timo Kuusi; François Mach; Naresh Ranjith; John Wikstrand
Journal:  Circulation       Date:  2009-11-16       Impact factor: 29.690

10.  Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure.

Authors:  Benjamin W Van Tassell; Ross A Arena; Stefano Toldo; Eleonora Mezzaroma; Tania Azam; Ignacio M Seropian; Keyur Shah; Justin Canada; Norbert F Voelkel; Charles A Dinarello; Antonio Abbate
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240
View more
  2 in total

1.  Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein.

Authors:  Cory R Trankle; Justin M Canada; Laura Cei; Nayef Abouzaki; Claudia Oddi-Erdle; Dinesh Kadariya; Sanah Christopher; Michele Viscusi; Marco Del Buono; Michael C Kontos; Ross Arena; Benjamin Van Tassell; Antonio Abbate
Journal:  Am J Cardiol       Date:  2018-07-20       Impact factor: 2.778

2.  Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure.

Authors:  George F Wohlford; Benjamin W Van Tassell; Hayley E Billingsley; Dinesh Kadariya; Justin M Canada; Salvatore Carbone; Virginia L Mihalick; Aldo Bonaventura; Alessandra Vecchié; Juan Guido Chiabrando; Edoardo Bressi; Georgia Thomas; Ai-Chen Ho; Amr A Marawan; Megan Dell; Cory R Trankle; Jeremy Turlington; Roshanak Markley; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2020-10-24       Impact factor: 3.271
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.